Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions
Prostate Cancer
Interventions
DRUG

QLG1080

Oral administration

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY